Quercetin + Dasatinib Interaction

⚠️ RESEARCH-BASED INTERACTION DATA — NOT COMPREHENSIVE.

Interaction Type: synergistic | Evidence Level: strong

The dasatinib + quercetin (D+Q) senolytic cocktail targets complementary anti-apoptotic pathways in senescent cells. Dasatinib targets tyrosine kinases while quercetin inhibits BCL-2/PI3K survival signaling.

Mechanism of Interaction

Senescent cells upregulate anti-apoptotic defense networks (SCAPs — Senescent Cell Anti-apoptotic Pathways). Dasatinib inhibits multiple tyrosine kinases (Src, Abl, c-Kit) that senescent cells depend on for survival. Quercetin inhibits PI3K, BCL-2 family proteins, and serpines. Together they target 6+ independent SCAP nodes, achieving senolytic effect neither achieves alone.

Clinical Relevance

D+Q is the most clinically studied senolytic combination. Phase I/II trials in diabetic kidney disease, idiopathic pulmonary fibrosis, and Alzheimer's disease. Intermittent dosing (3 days per month) minimizes side effects while effectively clearing senescent cells.

Recommendations

• Use intermittent 'hit-and-run' protocol: 3 consecutive days, then 28 days off
• Monitor CBC before and after each cycle (dasatinib hematologic effects)
• Quercetin dose: 1000mg; dasatinib dose: 100mg
• Not recommended for patients on anticoagulants without close monitoring

Relevant Conditions

• Age-related disease prevention
• Diabetic kidney disease
• Idiopathic pulmonary fibrosis
• Alzheimer's disease (exploratory)